[F-18]FDG and [C-11]Acetate PET/CT study for refractory diseases

[F-18]FDG and [C-11]Acetate PET/CT study for refractory diseases - [C-11]Acetate PET/CT study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023101

Enrollment

120

Registered

2016-07-15

Start date

2016-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancies and refractory or recurrent malignancies

Interventions

After intravenous administration of 3.7MBq/kg C-11 acetate, whole-body PET/CT is performed immediately. Subsequently, whole-body PET/CT is also performed 60 min after injection of 3.7MBq/kg F-18 FDG.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: i. [F-18]FDG PET/CT applicable for covered health insurance ii. greater than or equal to 20 years old iii. notification for malignant diseases iv. obtained informed consent by document

Exclusion criteria

Exclusion criteria: i. serum glucose level greater than 200mg/dl ii. pregnancy or possible iii. patients can't demonstrate informed consent iv. early gastric cancer in which [F-18]FDG PET/CT isn't applicable for covered health insurance

Design outcomes

Primary

Measure	Time frame
Accuracy to detect lesions	—

Secondary

Measure	Time frame
Inter- and intra-observer variability	—

Countries

Japan

Contacts

Public ContactUkihide Tateishi

Tokyo Medical and Dental University Diagnostic Radiology

ttisdrnm@tmd.ac.jp03-5803-5311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026